A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age by Perry, NSL et al.
 Accepted Manuscript
A randomised double-blind placebo-controlled pilot trial of a
combined extract of sage, rosemary and melissa, traditional herbal
medicines, on the enhancement of memory in normal healthy
subjects, including influence of age
N.S.L. Perry , R. Menzies , F. Hodgson , P. Wedgewood ,
M.-J.R. Howes , H.J. Brooker , K.A. Wesnes , E.K. Perry
PII: S0944-7113(17)30104-6
DOI: 10.1016/j.phymed.2017.08.015
Reference: PHYMED 52233
To appear in: Phytomedicine
Received date: 2 March 2017
Revised date: 11 June 2017
Accepted date: 15 August 2017
Please cite this article as: N.S.L. Perry , R. Menzies , F. Hodgson , P. Wedgewood ,
M.-J.R. Howes , H.J. Brooker , K.A. Wesnes , E.K. Perry , A randomised double-blind placebo-
controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines,
on the enhancement of memory in normal healthy subjects, including influence of age, Phytomedicine
(2017), doi: 10.1016/j.phymed.2017.08.015
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service
to our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and
all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
1 
 
A randomised double-blind placebo-controlled pilot trial of a combined extract of 
sage, rosemary and melissa, traditional herbal medicines, on the enhancement of 
memory in normal healthy subjects, including influence of age 
 
N.S.L. Perry
a,*
, R. Menzies
b
, F. Hodgson
b
, P. Wedgewood
b
, M.-J.R. Howes
c
, H. J. 
Brooker
d
, K. A. Wesnes
d
 and E.K. Perry
a
 
 
a
 Dilston Physic Garden, Corbridge, Northumberland, U.K. 
b
 The Body Works Centre, 4 Eastgate, Hexham, U.K. 
c
 Jodrell Laboratory, Royal Botanic Gardens, Kew, Richmond, urrey, U.K.  
d
 Wesnes Cognition Limited, Little Paddock, Streatley Hill, Streatley On Thames, U.K.  
 
*Corresponding author.  
Tel.: +7879 533875  
E-mail address: nic@dilstonphysicgarden.com (N. Perry). 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
2 
 
ABSTRACT 
Objective:  To evaluate for the first time the effects of a combination of sage, rosemary 
and melissa (Salvia officinalis L., Rosmarinus officinalis L. and Melissa officinalis L.; 
SRM), traditional European medicines, on verbal recall in normal healthy subjects.  To 
devise a suitable study design for assessing the clinical efficacy of traditional herbal 
medicines for memory and brain function.  
Methods:  Forty-four normal healthy subjects (mean age 61  9.26y SD; m/f 6/38) 
participated in this study.  A double-blind, randomised, placebo-controlled pilot study 
was performed with subjects randomised into an active and placebo group.  The study 
consisted of a single 2-week term ethanol extract of SRM that was chemically-
characterised using high resolution LC-UV-MS/MS analysis. Immediate and delayed 
word recall were used to assess memory after taking SRM or placebo (ethanol extract of 
Myrrhis odorata (L.) Scop.).  In addition analysis was performed with subjects divided 
into younger and older subgroups ( 62 years mean age n = 26: SRM n = 10, Placebo n 
= 16; ≥ 63 years n = 19: SRM n = 13, Placebo n = 6).   
Results:  Overall there were no significant differences between treatment and placebo 
change from baseline for immediate or delayed word recall.  However subgroup 
analysis showed significant improvements to delayed word recall in the under 63 year 
age group (p < 0.0123) with Cohen’s effect size d = 0.92.  No adverse effects were 
observed. 
Conclusion:  This pilot study indicates that an oral preparation of SRM at the selected 
dose and for the period of administration is more effective than a placebo in supported 
verbal episodic memory in healthy subjects under 63 years of age.  Short- and long- 
term supplementation with SRM extract merits more robust investigation as an 
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adjunctive treatment for patients with Alzheimer’s disease and in the general ageing 
population.  The study design proved a simple cost effective trial protocol to test the 
efficacy of herbal medicines on verbal episodic memory, with future studies including 
broader cognitive assessment. 
 
Keywords: 
Salvia officinalis; Rosmarinus officinalis; Melissa officinalis; Cognition; Word recall; 
Dementia; Traditional herbal medicine 
 
 
Abbreviations:  
LC-UV-MS/MS Liquid Chromatography-UltraViolet-Mass Spectroscopy,  RSM Rosemary, 
sage and melissa (Rosmarinus officinalis L., Salvia officinalis L., and Melissa officinalis 
L.). 
   
Introduction 
The need for therapeutic strategies to counter cognitive decline in our expanding aged 
populations and in dementia needs no highlighting these days (Prince et al. 2013).  It is 
reported that in the United States alone someone develops Alzheimer’s every 67 
seconds (Alzheimer's Dement., 2015).   Recent findings in the western world suggest 
the incidence may be in decline due to improved brain health and that specific anti-
Alzheimer's therapy should also combine preventative lifestyle interventions that target 
general brain health (Canevelli et al. 2016; Scheltens et al. 2016). In addition it is 
suggested that clinical studies (more relevant than animal studies) are key to finding 
effective treatments and preventative strategies (Pistollato et al. 2015).  
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Since the discovery of bioactivities of sage (Saliva officinalis L. and S. lavandulaefolia 
Vahl (the latter a synonym for S. officinalis subsp. lavandulifolia (Vahl) Gams) relevant 
to dementia therapy (Perry et al. 1998) several traditionally used medicinal plants have 
been found to enhance cognitive functions, including memory (Perry, Howes 2011) and 
to have actions associated with improving brain health such as antioxidant, anti-
inflammatory and neuroprotection  (Panickar 2013).  There is evidence, from both 
traditional herbal practice, as well as positive controlled clinical trials, that supports the 
use of natural products such as bacopa Bacopa monnieri (L.) Wettst. (Mathur et al. 
2016), curcumin (from turmeric, Curcuma longa L.) (Cox et al, 2015), huperzine A 
from Huperzia serrata (Thunb.) Trevis.) (Xu et al. 2012), Ginkgo biloba L. (Perry, 
Howes, 2011), peppermint (Mentha x piperita L.) (Moss et al., 2008), saffron (Crocus 
sativus L.) (Akhondzadeh et al., 2010), sage (Salvia officinalis L.), rosemary 
(Rosmarinus officinalis L.) and lemon balm (Melissa officinalis L.) in memory 
enhancement and/or slowing down age associated cognitive decline. 
   
Clinical and mechanistic studies support the cognitive enhancing effects of individual 
extracts of three European Lamiaceae medicinal plants for memory: sage (Perry et al. 
2003; Scholey et al. 2008; Tildesley et al. 2003), rosemary (Pengelly et al. 2012) and 
lemon balm; the latter also known by the vernacular name, melissa  (Kennedy et al. 
2003; Ozarowski, 2016) (SRM). These studies support their traditional use for cognitive 
function, however to date no study has examined clinical effects on memory of the 
specific SRM combination.  This, combined with the observed efficacy of SRM on 
outcome when prescribed by medical herbalists in patients experiencing memory loss, 
prompted the interest for a controlled pilot study of SRM.  The findings of this study 
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establish guidance for future similar pilot studies and outline for the first time the 
noteworthy effects of combined ethanol extracts of SRM. 
 
 
Subjects and methods  
The study was conducted at Dilston Physic Garden Centre and BodyWorks Therapy 
Centre (Northumberland, U.K.).  The protocol was approved by the Ethics Committee 
of Dilston Physic Garden and all subjects gave their informed consent.   
 
Subjects 
Subjects were screened and selected on the basis of key inclusion criteria of: age ≥40y 
and healthy with no reported current or previous clinical diagnosis of cognitive 
impairment or dementia.  Exclusion criteria were: use of warfarin, pregnancy and 
breastfeeding.  45 subjects met all criteria and participated (mean age 61  9.26y SD; 
m/f 6/38). All subjects were required to attend a local clinic (BodyWorks Therapy 
Centre) on two occasions, 2 weeks apart.  Subjects and administrators were blind to 
who was receiving the active (SRM) or placebo treatment. 
 
Study design  
A randomised, double-blind, placebo-controlled study design was performed.  Subjects 
were assigned 5ml SRM ethanol extract or 5ml placebo, diluted in warm water, 2x per 
day for 2 weeks.   
 
Memory test 
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A traditional pencil and paper immediate and delayed word recall test to assess verbal 
working and episodic memory (Moss et al 2008), performed at the pre-dose (baseline 
assessment) and at the end of the 14 day treatment period. 
 
Word recall 
A total of 15 words were displayed to the subject one at a time using laminated sheets 
(with different lists at each visit).  Immediately after seeing the words the subjects were 
given 1 min to write down as many words as they could recall seeing (Immediate Word 
Recall – Verbal Working Memory).  Subjects were then given a 10 min break in which 
they were given reading materials and asked to remain in the assessment room.  After 
this controlled period of time subjects were again given 1 min to write down as many of 
the words as they could recall seeing (Delayed Word Recall – Verbal Episodic Memory.  
 
Statistical analyses 
All analyses were conducted using the SAS statistical package Version 9.4 (SAS 
Institute Inc., Cary, NC, USA). All values are shown as mean  SE.  Change from 
baseline scores were calculated and submitted to analysis of variance using the MIXED 
procedure. Cohen’s d effect sizes were calculated to identify the magnitude of any 
differences between dosing condition.  Statistical significance was defined as a two-
sided p value less than 0.05. 
 
Extracts  
The SRM extract consisted of extracts of 3 medicinal plant species from the Lamiaceae, 
each having a long standing safety record from traditional use and commercial food or 
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beverage production.  Fresh authenticated plant material of Salvia officinalis L. 
(authentication code 140613-4/2), Rosmarinus officinalis L. (authentication code 
140618-1/1) and Melissa officinalis L. (authentication code 130918-2/2), collected and 
individually extracted 0.5 g/ml in 45% EtOH for 3 weeks in the dark at room 
temperature, were grown (on site) and supplied by Rutland Biodynamic, Town Park 
Farm, Brooke, Rutland LE15 8DG United Kingdom.  Plant names were checked with 
the World Checklist of Selected Plant Families (http://apps.kew.org/wcsp/home.do) and 
all plants were grown to organic and biodynamic standards.  The extracts were 
combined in equal proportions (equivalent to daily dose 5g original plant material) and 
separated into 50 ml bottles.   
 
The placebo was 50% fresh sweet cicely [Myrrhis odorata (L.) Scop.; Apiaceae]  
extract (1 g/ml 45% EtOH extracted at room temperature for 3 weeks), not known to 
affect brain function, to provide a non-cognitive control and to mask the SRM.  1% 
Lyles Black Treacle (Waitrose Ltd, UK.), used as a colorant to mask SRM, was added 
to both SRM and placebo.   Cicely extract was added as 10% of the total volume to both 
SRM and placebo preparations.  
 
LC-UV-MS/MS Analysis  
The extracts were diluted 1:4 in 70% aqueous ethanol prior to analysis using a Thermo 
Scientific system consisting of an ‘Accela’ U-HPLC unit with a photodiode array 
detector and an ‘LTQ Orbitrap XL’ MS with an electrospray source (Thermo Scientific, 
Waltham, MA, USA). Chromatography was performed on 5 µl sample injections onto a 
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150mm x 3mm, 3µm Luna C-18 column (Phenomenex, Torrance, CA, USA) using the 
following 400 µl/min mobile phase gradient; H2O:CH3OH:CH3CN + 1% HCOOH: 
90:0:10 (0 min), 90:0:10 (5 min), 0:90:10 (60 min), 0:90:10 (65 min), 90:0:10 (67 min), 
90:0:10 (70 min) followed by return to start conditions and equilibration in start 
conditions for 5 min before the next injection. The ESI source was operated with 
polarity switching and the MS recorded high resolution (30 k resolution) MS1 spectra 
(m/z 125–2000) in positive mode and low resolution MS1 spectra (m/z 125– 2000) in 
negative mode and data dependent MS2 and MS3 spectra in both modes using the linear 
ion trap. Detected compounds were assigned by comparison of accurate mass data 
(based on ppm), and by available MS/MS data, with reference to the published 
compound assignment system (Schyanski et al., 2014) and with supportive UV spectra. 
Diterpenoids were also assigned by comparison with a reference standard of rosmanol 
(≥ 99% purity) (LGC Ltd, UK). 
 
 
Results  
Of the 45 subjects recruited 44 completed the pre and post dose test sessions at baseline 
and the 14 day follow up (Male = 6; Female = 38).  There were no side effects observed 
in any subject.  The treatment groups matched with 22 in each group (Table 1).   
 
Memory test  
The number of words correctly recalled, minus the number of words recalled in error 
(intrusions) were calculated for both immediate and delayed word recall at each visit.  
Changes from baseline comparisons between the SRM group to the placebo group were 
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analysed and whilst the treatment group did perform marginally less well at baseline, 
this difference between the groups did not approach statistical significance in either.   
 
On further analysis there were no changes over time in either placebo or SRM or in 
differences between the two which approached statistical reliability, although 
numerically the SRM group did tend to improve more in delayed word recall.  Analysis 
was conducted to establish any noteworthy effects for future studies.   No benefits were 
found when analysing by gender, baseline scores or when excluding those who had 
missed >3 doses.   
 
Although not noted during randomisation, the placebo group was on average 4.5 years 
younger than the SRM group (SRM mean age 63.05y  8.7SD; placebo mean age 
58.59y  9.3SD) and this approached statistical significance (p = 0.11).  The population 
was divided into two subgroups Younger and Older (Table 1) and the subgroups 
matched by age range (Younger 43-62 years: placebo 43-62y and SRM 44-61y; Older 
63-80y: placebo 66-78y, SRM 63-80y) and disperse the gender of this population within 
the subgroups (female 86% overall populations: Younger M = 2, F = 24; Older M = 4, F 
= 14). 
 
The subgroups were analysed separately using baseline performance as the covariate.  
This analysis showed a main effect in delayed word recall for the younger subgroup 
taking SRM compared to placebo (p = 0.0347) (Table 2, Fig. 1).  This improvement in 
the treatment group over baseline represents 2.6 words (p = 0.0123) which is a 56% 
improvement over baseline, with a Cohen’s effect size of d = 0.92.  Treatment 
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compliance was similar in the 2 overall groups, but slightly less in the older group 
(average declared missed dose of 2.2) compared to the younger group (average declared 
missed dose of 1.5). 
 
Phytochemical analysis  
The LC-MS chromatograms for each SRM extract and the SRM combination are shown 
in Fig. 2. Phytochemical analysis revealed the compounds detected in the three 
Lamiaceae species are in agreement with published literature for these species (British 
Pharmacopeia, 2014; CCD, 2016; Fecka and Turek, 2007; Heitz et al., 2000; 
Kontogianni et al., 2013). The main compound classes detected in the three extracts and 
the SRM combination using LC-MS were flavones and their glycosides (1, 2, 3, 5, 6, 7, 
8, 9, 10, 12), diterpenoids (11, 13, 14, 15, 16) and rosmarinic acid (4) (Fig. 2). The 
flavones and their glycosides, and rosmarinic acid, were assigned from their observed 
[M+H]
+
 ions, with supportive UV spectra and MS/MS interpretation. Compounds 
assigned as diterpenoids were only detected in the S. officinalis and R. officinalis 
extracts; therefore their detection in the SRM combination was due to these species and 
not M. officinalis, in which diterpenoids were not detected.  
A compound with m/z 347.1845 eluting
 
at the retention time (Rt) 36.5 min (11) was 
assigned as C20H26O5 from the observed [M+H]
+
 ion and was designated as rosmanol, a 
diterpenoid known to occur in both S. officinalis and R. officinalis (Miura et al., 2001; 
Borrás Linares et al., 2011). At Rt 39.8 min (m/z 377.1581) a compound (13) was 
designated the molecular formula C20H24O7 from the observed [M+H]
+
 ion, which was 
proposed to be an abietane diterpenoid (or isomer) previously reported to occur in S. 
gilliesii Benth. [synonym for S. cuspidata subsp. gilliesii (Benth.) J.R.I.Wood] and in S. 
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palaestina Benth. [6,12,19-trihydroxy-11,14-diketo-8,12-abietadien-20,7-olide and 
salvipalestinoic acid, respectively] (Nieto et al., 2000; CCD, 2016). 
 
A compound (14) eluting at 45.6 min with m/z 405.1896 was assigned with the 
molecular formula C22H28O7, determined from the [M+H]
+
 ion, which is the molecular 
formula of dihydroxy-clerodadiene-diolide, and is known to occur in Salvia species 
(CCD, 2016). With supportive MS/MS interpretation, the molecular formula C22H30O5 
was designated to the compound (15) eluting at Rt 48.1 min with m/z 375.2151, and is 
that of the ethyl ether derivative of rosmanol (or isomer). Indeed, 7-ethoxyrosmanol, 
epiisorosmanol ethyl ether (Borrás Linares et al., 2011) and epirosmanol ethyl ether 
(Zhang et al., 2012) are proposed to occur in R. officinalis; whilst the 9-ethyl ether 
derivative of rosmanol is reported in S. officinalis (Djarmati et al., 1991). The 
compound (16) eluting at 54.6 min, with m/z 715.4154, was assigned as a methyl ether 
derivative of carnosic acid from the observed [2M + Na]
+ 
ion, with the molecular 
formula calculated as C21H30O4. The 12-methyl ether derivative of carnosic acid has 
previously been reported to occur in R. officinalis (CCD, 2016) and has also been 
known as methyl carnosate (Zhang et al., 2012).  
 
Discussion 
This pilot study using a combined extract of sage, rosemary and melissa in healthy 
subjects for the first time, shows encouraging indications of value in supporting 
memory in brain health and disorders of memory impairment.  Results support findings 
of previous cognitive benefits of the individual extracts (Kennedy et al. 2003; Pengelly 
et al. 2012; Scholey et al. 2008).  
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The mechanisms behind the delayed word recall effects are likely to be due to 
anticholinesterase actions of these species and due to the interactions of their 
constituents such as Lamiaceae monoterpenoids (1,8-cineole, α-pinene, borneol and 
camphor) and other constituents such as rosmarinic acid, and/or their metabolites 
(Williams et al., 2011). The anticholinesterase activity of a rosemary extract was 
concluded to explain its memory-enhancing effect in a scopolamine-induced animal 
model of dementia (Habtemariam, 2016) and reduced levels of AChE were found in rat 
brain following oral administration of sage essential oil, suggesting monoterpenoids 
present in orally taken extracts of sage, rosemary and melissa can reach the brain (Perry 
et al., 2003). 
Other mechanisms of action of constituents present in the extracts may also be 
responsible such as cholinergic receptor activation (Kennedy et al. 2003) and, though 
more likely evident with longer term treatment, anti-inflammatory, antioxidative (such 
as pinenes, geraniol and apigenin or metabolites), anti-amyloid, oestrogenic and 
neuroprotective actions of terpenoids and phenolics or their metabolites present in these 
species may play a role (Howes and Houghton, 2012; Huang et al, 2008; Oliveira 2015; 
Porres-Martínez et al. 2015; Soodi et al, 2017). Rosemary and sage terpenoids are 
associated with a range of antioxidant, anti-inflammatory and anti-amyloid mechanisms 
that have been considered to contribute to the cognitive enhancing effects of extracts 
(Habtemariam, 2016). Rosmanol, a diterpenoid detected in the SRM combination, has 
been suggested as a potent anti-inflammatory agent (Lai et al., 2009). However, whilst 
rosemary diterpenoids (including carnosic acid methyl ether, detected in the SRM) have 
been associated with potent antioxidant effects, it has been suggested that their 
antioxidant potency is reduced during the digestion process and digestive products of 
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the diterpenoids may mediate antioxidant effects following their oral ingestion (Soler-
Rivas et al., 2010). Regarding bioavailability, one study associated rosemary flavonoids 
with passive diffusion in Caco-2 cells to predict their intestinal absorption, with 
cirsimaritin (detected in SRM) having amongst the highest permeation potency; 
although rosemary diterpenoids including rosmanol (detected in SRM) demonstrated 
even higher permeability (Pérez-Sánchez et al., 2017). Thus, the flavonoid, 
monoterpenoid, and diterpenoid constituents in SRM may be adequately bioavailable to 
contribute to the observed effects of SRM on cognitive functions in the present study. In 
general, it has been concluded that flavonoids are poorly absorbed following oral 
administration and are extensively metabolised in the intestine and liver (Lotito and Frei, 
2006). Furthermore, studies using an in vitro model of the blood-brain barrier (BBB) 
indicate some flavonoids and their glucuronide metabolites may be able to cross the 
BBB; and in vivo, flavonoid aglycones were detected in rat brain tissue following oral 
administration of flavonoid glycosides (Jäger and Saaby, 2011). Other studies associate 
diterpenoids from Salvia species with clogP values indicative of their ability to cross the 
blood-brain barrier (Ren et al., 2004). The results from our study associate SRM with 
improved verbal episodic memory in healthy subjects under 63 years of age, compared 
to placebo, thus indicate that constituents of SRM, or their metabolites, are adequately 
bioavailable and cross the BBB. This concurs with previous studies where oral 
administration of members of the Lamiaceae is associated with improved cognitive 
functions in controlled trials (Perry and Howes, 2011). We therefore emphasise the need 
for continued investigations on the pharmacokinetics of plant species and their 
constituents to further elucidate their therapeutic potential for use in cognitive disorders. 
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It is notable that rosmarinic acid modulates a range of pathways implicated in 
Alzheimer’s pathology, including amyloid accumulation, DNA fragmentation, capase-3 
activation and tau protein hyperphosphorylation (Williams et al., 2011), therefore its 
detection in all three Lamaiceae species in the SRM extract is of particular relevance 
when investigating plant species to favourably impact against cognitive decline. 
Subchronic oral administration of rosmarinic acid to rats (2 mg/mg for 2 or 3 weeks) 
enhanced cognitive performance (Park et al., 2010), thus indicating the potential 
relevance of this phenolic acid (or its metabolites) for cognitive functions. However, 
more studies on the bioavailability and pharmacokinetics of rosmarinic acid (and other 
phenolic/ terpenoid constituents present) in humans, and the ability of rosmarinic acid, 
and others such as salvianolic acid, metabolites to cross the blood-brain barrier, are 
needed to more fully elucidate its clinical relevance. Recent studies reveal that 
rosmarinic acid has poor oral bioavailability [< 2% in vivo] (Wang et al., 2017), but in 
humans it is rapidly absorbed following oral administration prior to methylation and 
conjugation by glucuronidation and/or sulfation, with one of the major metabolites 
reported as trimethoxycinnamic acid monoglucuronide; whilst it is important to 
consider that pharmacokinetics studies in animals report different metabolites to those 
observed in humans (Amoah et al., 2016).  Other studies provide conflicting results on 
whether rosmarinic acid and/or its metabolites can cross the BBB, with rosmarinic acid 
not detected in the brain of rats following intragastric administration of an extract 
prepared from another Lamiaceae species (Plectranthus barbatus Andrews); but 
detection of rosmarinic acid was observed in rat brain following intraperitoneal 
administration of the same preparation (Falé et al., 2011).  
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Future combination therapy could consider addition of other plant extracts reputed to 
counter cognitive decline, including bacopa (Bacopa monnieri (L.) Wettst.), clubmoss 
(Huperzia serrata (Thunb.) Trevis.) and ginseng (Panax ginseng C.A.Mey.), nigella 
(Nigella sativa L.), periwinkle (Catharanthus roseus L.), ashwagandha (Withania 
somnifera L.) and turmeric (Curcuma longa L.) amongst others (Perry and Howes, 
2011).  Plants that have other beneficial mechanistic effects, such as increasing blood 
flow and cholesterol metabolism, and benefits for behavioural symptoms such as anti-
agitation (for example chamomile (Matricaria chamomilla L.), passion flower 
(Passiflora species)) and sleep enhancers (such as lavender (Lavandula angustifolia 
Mill.) and valerian (Valeriana officinalis L.)) may also provide the warranted 
polypharmaceutical (and even preventative) approach to multifaceted disease processes 
such as Alzheimer’s (Akhondzadeh et al. 2010; Ji et al, 2011; Perry and Howes 2011; 
Russo et al. 2013).  
 
The absence of any effect in the older population was unexpected, and may reflect the 
need for a higher dose and/or treatment duration in individuals whose cerebral function 
may be compromised by age; and also as a preventative agent to help prevent long term 
memory decline given the additional antioxidative and anti-inflammatory properties of 
such plant species.  Since a major objective of this pilot controlled trial was to 
investigate medicinal plants to counter age associated cognitive decline, the results have 
indicated the value for a future trial, with a longer duration, more extensive cognitive 
assessments, SRM at a higher dose or using other methods of administration to assess 
and enhance bioavailability.  A recent 20-year follow-up population-based study 
concluded that cognitive decline in a non-demented elderly population was lower in 
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subjects who took Ginkgo biloba compared to those who did not (Amieva et al., 2013), 
equally indicates a longer term trial may be relevant to examine the preventative 
potential of medicinal plants for dementia, given the numerous and polypharmacologic 
neuromechanisms behind a number of these plants and considering their relative safety 
of use. Furthermore, for future medicinal plant clinical studies in general, care should be 
taken with patient cohorts to allow for any potential contraindications (S. officinalis in 
epilepsy) and adverse effects of specific doses of sage (blood pressure), melissa and 
rosemary (anxiety) (Pengelly et al. 2012; Scholey et al. 2014).   
 
For the majority of plant medicines, there are few robust clinical trials to assess their 
efficacy, with the major issue for many trials to date being the investigation of plant 
medicines that are not adequately authenticated or chemically-characterised. The type of 
extract and the ability of the ‘active’ compounds to cross the blood-brain barrier to 
reach the CNS must also be considered.  In addition to characterising phytochemical 
differences (or similarities), exploring alternative methods of administration may also 
be key to discrepancies between laboratory and clinical data (McClure et al. 2015), 
although the explicit phytochemical analysis and characterisation of extracts remains 
primary in this objective. 
 
Conclusion 
This double-blind, placebo-controlled pilot study has left clear water for piloting other 
plant medicines (and their combinations) by this method, demonstrating a simple cost 
effective model that could be used clinically by medical herbalists, aromatherapists and 
in other clinical settings to test efficacy.  All future pilot studies of medicinal plants will 
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benefit from a randomised double-blind placebo-controlled cross-over design and 
increased scope of cognitive function testing, that would provide more robust 
(cognitive) data and understanding of the therapeutic indications of SRM (and other 
chemically-characterised polyherbal formulations), not only for core aspects of 
cognitive function known to decline with age, but for other CNS disorders such as 
anxiety, depression, sleep and pain.   
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Fig. 1. Delayed Word Recall in the Younger (63) and Older (≥ 63 years) 
Subgroups mean change from baseline. [colour] 
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Fig. 2. LC-MS chromatograms (positive mode) of the S. officinalis, R. officinalis and M. 
officinalis extracts and the SRM extract combination. Assigned compounds: (1) luteolin 
7,4ʹ-di-O-glucuronide; (2) luteolin 7-O-glucoside; (3) luteolin 7-O-glucuronide; (4) 
rosmarinic acid; (5) chrysoeriol 7-O-glucuronide; (6) luteolin 3ʹ-O-glucuronide; (7) 
luteolin; (8) 6-methoxyluteolin; (9) apigenin; (10) scutellarein 6-methyl ether; (11) 
rosmanol; (12) cirsimaritin; (13) diterpenoid: C20H24O7; (14) dihydroxy-clerodadiene-
diolide; (15) rosmanol ethyl ether; (16) carnosic acid methyl ether. 
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Table 1 Subject subgroup characteristics 
Group Treatment N Gender Age Mean SD Min Max Group 
Older SRM 10 Female 69.50 4.9 63.00 80.00 63 to 
80 ≥ 63 years SRM 2 Male 68.50 7.7 63.00 74.00 
 
Placebo  4 Female 70.50 5.2 66.00 78.00 66 to 
78 
 
Placebo  2 Male 68.00 . 68.00 68.00 
        
 
Younger SRM 9 Female 55.44 6.1 44.00 61.00 44 to 
61 (62years) SRM 1 Male 56.00 . 56.00 56.00 
 
Placebo  15 Female 54.27 7.2 43.00 62.00 43 to 
62   Placebo  1 Male 57.00 . 57.00 57.00 
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Table 2  
Immediate and delayed word recall results by subgroup and treatment  
Subgroup Treatment N Visit Test Mean number of words recalled SE 
OLDER SRM n = 12 Baseline  Immediate Word Recall  6 0.86 
 ≥ 63 years  
  
Baseline  Delayed Word Recall 4.16 0.99 
   
14 days Immediate Word Recall  6 0.75 
   
14 days Delayed Word Recall 3.5 0.85 
 
Placebo  n = 6 Baseline  Immediate Word Recall  6.16 0.74 
   
Baseline  Delayed Word Recall 5 0.81 
   
14 days Immediate Word Recall  6.16 0.79 
   
14 days Delayed Word Recall 4.5 1.11 
YOUNGER SRM n = 10 Baseline  Immediate Word Recall  6.9 1.02 
62 years 
  
Baseline  Delayed Word Recall 4.6 0.71 
   
14 days Immediate Word Recall  7.2 1.13 
   
14 days Delayed Word Recall 7.2 1.29 
 
Placebo  n = 16 Baseline  Immediate Word Recall  7.37 0.83 
   
Baseline  Delayed Word Recall 5.62 0.81 
   
14 days Immediate Word Recall  7.31 0.59 
      14 days Delayed Word Recall 5.37 0.75 
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